hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06283992 id: 2024p000095 id: K23MD016439 type: NIH link: https://reporter.nih.gov/quickSearch/K23MD016439 briefTitle: Digital Health Navigation for Latino Patients With Type II Diabetes overallStatus: RECRUITING date: 2024-03-31 date: 2026-05-31 date: 2027-05-31 date: 2024-02-28 date: 2024-03-28 name: Brigham and Women's Hospital class: OTHER name: National Institute on Minority Health and Health Disparities (NIMHD) briefSummary: The goal of this clinical trial is to learn about digital literacy training in adult, Latino patient with type II diabetes. The main question it aims to answer is: Can providing digital literacy training during a hospital admission can help patients with their after-hospital care by using the patient portal and telehealth? Participants will receive digital literacy training by a digital navigator that focuses on the main patient portal functions. Researchers will compare patients who receive digital literacy training to those who receive standard of care (educational sheet) to see if it impacts their use of the patient portal after discharge. conditions: Type 2 Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Researchers will compare effectiveness between two arms: 1) patient education using a digital navigator on using digital tools after discharge and 2) usual care (educational sheet). primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 84 type: ESTIMATED name: Digital Navigation measure: Proportion of Participants Who Login to the Portal measure: Proportion of Participants that Perform Distinct Portal Functions measure: Proportion of participants that complete a telehealth measure: Proportion of participants that are re-admitted sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02120 country: United States name: Jorge A Rodriguez, MD role: CONTACT lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06283979 id: 199723 briefTitle: A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers. acronym: BLADE OPU2 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-01 date: 2025-12-01 date: 2024-02-28 date: 2024-02-29 name: Biocomposites Ltd class: INDUSTRY name: MCRA briefSummary: The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers. conditions: Pressure Ulcer, Stage IV conditions: Osteomyelitis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: STIMULAN VG name: Standard of Care measure: Individual patient success and findings at the 8 week follow-up visit sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283953 id: 2023P001695 id: IHS-2022C1-26100 type: OTHER_GRANT domain: Patient Centered Outcomes Research Institute (PCORI) briefTitle: Boosting Resources for Tracheostomy Care at Home acronym: BREATHE overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-01 date: 2027-10-01 date: 2024-02-28 date: 2024-02-28 name: Massachusetts General Hospital class: OTHER name: Children's Hospital Medical Center, Cincinnati name: Children's Hospital of Philadelphia name: Children's Hospitals and Clinics of Minnesota name: Children's National Research Institute name: Rady Children's Hospital, San Diego name: Patient-Centered Outcomes Research Institute briefSummary: The goal of this trial is to advance our understanding of how to best support caregivers of children with tracheostomies who are caring for their child at home. The main questions it aims to answer are:
Caregiver participants will be randomly assigned to receive Trach Me Home (gold standard discharge program) or Trach Me Home with additional components. Caregiver participants will complete three surveys over the course of 6 months. Researchers will see if caregivers in the Trach Me Home with additional components report lower caregiver burden at 4 weeks post discharge (primary outcome) and fewer hospital readmissions at 6 months than those in Trach Me Home arm. conditions: Tracheostomy conditions: Caregiver Burden studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: Blinding of care team delivering the interventions and of caregiver participants receiving the interventions is not possible for this study.
The outcome assessors collecting the readmission data and statistician conducting analyses will be blinded to the assignment. whoMasked: OUTCOMES_ASSESSOR count: 480 type: ESTIMATED name: Trach@Home name: Trach Me Home measure: Caregiver Burden measure: Medical Complications Associated with Tracheostomy measure: 6-month Readmission Rate measure: Frequency of pediatrician communication measure: Primary care pediatrician satisfaction measure: Medical Complications Associated with Tracheostomy measure: Caregiver Burden measure: Number of readmissions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of San Diego Rady Children's Hospital city: La Jolla state: California zip: 92093 country: United States name: Matthew Brigger, MD role: CONTACT email: mbrigger@rchsd.org name: Matthew Brigger, MD role: PRINCIPAL_INVESTIGATOR lat: 32.84727 lon: -117.2742 facility: Children's National Medical Center, Children's Research Institute city: Silver Spring state: Maryland zip: 20910 country: United States name: Habib Zalzal, MD role: CONTACT email: hzalzal@cnmc.org name: Habib Zalzal, MD role: PRINCIPAL_INVESTIGATOR lat: 38.99067 lon: -77.02609 facility: Massachusetts General Hospital city: Boston state: Massachusetts zip: 02114 country: United States name: Karen Sepucha, PhD role: CONTACT email: ksepucha@mgh.harvard.edu name: Christopher Hartnick, MD role: CONTACT lat: 42.35843 lon: -71.05977 facility: Children's Hospitals and Clinics of Minnesota city: Minneapolis state: Minnesota zip: 55404 country: United States name: Asitha Jayawardena, MD role: CONTACT email: asitha.jayawardena@childrensmn.org name: Asitha Jayawardena, MD role: PRINCIPAL_INVESTIGATOR lat: 44.97997 lon: -93.26384 facility: Cincinnati Children's Hospital Medical Center city: Cincinnati state: Ohio zip: 45229 country: United States name: Matthew Smith, MD role: CONTACT email: matthew.smith@cchmc.org name: Matthew Smith, MD role: PRINCIPAL_INVESTIGATOR lat: 39.12713 lon: -84.51435 facility: Children's Hospital of Philadelphia city: Philadelphia state: Pennsylvania zip: 19146 country: United States name: Luv Javia, MD role: CONTACT email: javia@chop.edu name: Luv Javia, MD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06283940 id: 281694 briefTitle: Exercise-based Cardiac Rehabilitation in Patients With Aortic Stenosis After Transcatheter Aortic Valve Implantation acronym: TAVI overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-01 date: 2026-01 date: 2024-02-28 date: 2024-04-24 name: Vastra Gotaland Region class: OTHER_GOV briefSummary: Aortic valve stenosis (AS) is the most common valve disease among older individuals. In symptomatic AS, mortality is high, and the only treatment that improves prognosis and survival is transcatheter aortic valve implantation (TAVI). TAVI is a growing treatment in Sweden, allowing previously inoperable older patients with AS, who are often frail and have comorbidities, to receive intervention. This results in the need for postoperative cardiac rehabilitation for patients treated with TAVI. Previous systematic reviews and meta-analyses examining the effect of physiotherapist-led exercise-based cardiac rehabilitation (PT-X) after TAVI have shown that participation in PT-X can improve physical fitness (the highest measured oxygen uptake (VO2peak)), walking distance, walking speed, and health-related quality of life (HR-QoL). However, the included studies are limited, and there is selection bias, resulting in low evidence. Therefore, access to PT-X is currently almost non-existent in Sweden. As more patients undergo TAVI, it is crucial to investigate whether PT-X after TAVI can further improve physical fitness, HR-QoL, and reduce hospital admissions in older individuals with AS.
Expected outcome: If patients with AS who have undergone TAVI can improve physical fitness, it could potentially strengthen the evidence and optimize the patient's physical capabilities. Increased access to PT-X and awareness of frailty in these patients could reduce the risk of falls and possibly the number of hospital readmissions. This would decrease healthcare consumption and improve the patient's quality of life. conditions: Aortic Valve Stenosis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention group and matched controls based on age, gender and exercise capacity in watt. primaryPurpose: TREATMENT masking: NONE maskingDescription: Data collection will be conducted by a physiotherapist not involved in the intervention. count: 135 type: ESTIMATED name: Physiotherapist-led exercise based cardiac rehabilitation (PT-X) measure: Exercise capacity in watt measure: Rating of perceived exertion Borg RPE scale 6-20 measure: Exercise capacity in Watt measure: Rating of perceived exertion Borg RPE scale 6-20 measure: Muscular endurance test, shoulder flexion measure: Muscular endurance test, shoulder flexion measure: Muscle endurance test, shoulder abduction measure: Muscle endurance test, shoulder abduction measure: Muscle endurance test, unilateral heel-lift measure: Muscle endurance test, unilateral heel-lift measure: Lower extremity function measure: Lower extremity function measure: Physical activity measure: Physical activity measure: Self-assessed level of physical activity measure: Self-assessed level of physical activity measure: Health Related Quality of Life measure: Health Related Quality of Life measure: Frailty measure: Frailty measure: Hospital admission measure: Hospital admission sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283927 id: MEC-2020-0812-5 briefTitle: The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) acronym: RECSUR overallStatus: RECRUITING date: 2023-01-01 date: 2027-01-01 date: 2028-01-01 date: 2024-02-28 date: 2024-02-28 name: Jasper Gerritsen class: OTHER name: Haaglanden Medical Centre name: Universitaire Ziekenhuizen KU Leuven name: University Hospital Heidelberg name: Technical University of Munich name: Insel Gruppe AG, University Hospital Bern name: Massachusetts General Hospital name: University of California, San Francisco briefSummary: Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecular patient subgroups remains ill-defined. The aim of this study, therefore, is to compare the effects of resection and best oncological treatment for recurrent glioblastoma as a whole and in clinically important subgroups.
This study is an international, multicenter, prospective observational cohort study. Recurrent glioblastoma patients will undergo tumor resection or best oncological treatment at a 1:1 ratio as decided by the tumor board. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks after surgery and 2) overall survival. Secondary endpoints are: 1) progression-free survival (PFS), 2) NIHSS deterioration at 3 months and 6 months after surgery, 3) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.
nctId: NCT06283914 id: BIO-2024-0011 briefTitle: Imputation of Arterial Oxygen Partial Pressures Using Pulse Oximetry overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-01 date: 2024-09-01 date: 2024-02-28 date: 2024-02-28 name: American University of Beirut Medical Center class: OTHER briefSummary: The goal of this is prospective cohort study is to to study the relationship between PaO2 and SpO2 in the overall population undergoing general anesthesia in the OT. Secondary aims include studying the relationship between PaO2 and SpO2 in elderly and obese patients undergoing general anesthesia in the OT, validating the derivation of PaO2 from SpO2 using formulas derived by Rice et al. (2009), Pandharipande et al. (2009), and Gadrey et al. (2019) in patients undergoing general anesthesia in the OT, and, if the derivation formulas were not valid, to derive a formula for patients undergoing general anesthesia in the OT.
The included blood samples are arterial blood sample collected for ABGs analysis through either an arterial catheter or an arterial blood puncture in adult patients (Age \>18 years) undergoing general anesthesia regardless of the acuity of the surgery (elective, emergency, or lifesaving), the hemodynamic stability of the patient, or the comorbidities. Patients undergoing cardiac or thoracic surgeries will be excluded. conditions: Oxygen Saturation conditions: Respiratory Distress Syndrome conditions: Anesthesia, General studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: PaO2 measure: SpO2 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283901 id: NL82013.018.22 briefTitle: Improving Diagnosis and Prediction of Outcome in Patients With Severe Disorders of Consciousness acronym: IMPROVE-DOC overallStatus: RECRUITING date: 2023-01-02 date: 2025-01-01 date: 2025-09-01 date: 2024-02-28 date: 2024-02-28 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER briefSummary: Patients with acute severe brain injury are usually admitted to the Intensive Care Unit. A substantial proportion of these patients will have disorders of consciousness (DOC) after interruption of sedation. It is difficult to reliably predict neurological outcome in these patients. Dependent on the extent of permanently damaged brain areas, DOC in patients with acute severe brain injury may improve or persist, eventually evolving into a minimal conscious state (MCS) or unresponsive wakefulness syndrome (UWS). These conditions are accompanied by long term severe disability. In current practice, the decision to withdraw life-sustaining support is made by interpreting the results of repeated bedside neurological examination and conventional CT-brain imaging. Reliable identification of patients with a possible good outcome, in whom treatment should not be withdrawn, is difficult. In this prospective observational cohort study we aim to identify patients with a good neurological outcome. conditions: Traumatic Brain Injury conditions: Intracranial Hemorrhages conditions: Subarachnoid Hemorrhage conditions: Meningitis conditions: Encephalitis conditions: Stroke studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 160 type: ESTIMATED measure: Glasgow Outcome Scale Extended measure: Glasgow Outcome Scale Extended sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Radboud UMC status: RECRUITING city: Nijmegen state: Gelderland zip: 6525 GA country: Netherlands name: Astrid Hoedemaekers role: CONTACT lat: 51.8425 lon: 5.85278 facility: Amsterdam UMC status: RECRUITING city: Amsterdam state: Noord-Holland zip: 1105 AZ country: Netherlands name: Wolmet Haksteen, MD role: CONTACT phone: +31 020 - 566 9111 email: w.e.haksteen@amsterdamumc.nl lat: 52.37403 lon: 4.88969 facility: Haaglanden MC, locatie Westeinde status: RECRUITING city: Den Haag state: Zuid-Holland zip: 2512 VA country: Netherlands name: Sefanja Achterberg role: CONTACT lat: 52.07667 lon: 4.29861 facility: Erasmus MC status: NOT_YET_RECRUITING city: Rotterdam state: Zuid-Holland zip: 3015 GD country: Netherlands name: Mathieu van der Jagt role: CONTACT lat: 51.9225 lon: 4.47917 facility: UMC Groningen status: NOT_YET_RECRUITING city: Groningen zip: 9713 GZ country: Netherlands name: Joukje van der Naalt role: CONTACT lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06283888 id: PRECISE-PCI briefTitle: CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention overallStatus: RECRUITING date: 2024-04-01 date: 2028-04-01 date: 2028-12-01 date: 2024-02-28 date: 2024-03-20 name: Zunyi Medical College class: OTHER briefSummary: In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard DAPT. Although better understood "East Asian Paradox", finding the right CYP2C19 genotype-guided P2Y12 inhibitor selection to balance maintaining ischaemic prevention and less bleeding remains a topic in real-world clinical practice. conditions: ACS - Acute Coronary Syndrome conditions: CYP2C19 Polymorphism studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1200 type: ESTIMATED name: CYP2C19 Genotype Guided DAPT name: Conventional DAPT measure: NACE (net adverse clinical event) measure: Incidence of clinically significant bleeding measure: Incidence of MACCE sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affiliated Hospital of Zunyi Medical University status: RECRUITING city: Zunyi state: Guizhou zip: 563003 country: China name: Cai De Jin, MD role: CONTACT phone: 86+173-8576-9997 email: jincaide@zmu.edu.cn name: Yan Yan Jin, MD, PhD role: CONTACT phone: 86+157-7229-0925 email: jinyanyan850925@163.com name: Cai De Jin, MD role: PRINCIPAL_INVESTIGATOR name: Ran Zun Zhao, MD role: SUB_INVESTIGATOR lat: 27.68667 lon: 106.90722 hasResults: False
nctId: NCT06283875 id: PROMISEPLUS-301 briefTitle: The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-01-30 date: 2029-01-30 date: 2024-02-28 date: 2024-02-28 name: Geneplus-Beijing Co. Ltd. class: INDUSTRY briefSummary: This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA) confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are expected to receive surgical resection or curative radiotherapy and chemotherapy. Collect baseline tumor tissue samples from patients during the treatment period, as well as peripheral blood samples (20 ml/time) from multiple treatment timepoints. Mutations in tumor tissue were detected by the 1021 genes panel, then personalized MRD monitoring probes were customized for patients, allowing for multi node peripheral blood sample ctDNA detection of enrolled patients. The clinical significance of ctDNA in prognostic stratification, recurrence monitoring, and efficacy prediction in surgical/non-surgical cervical cancer patients was explored. And compare the consistency and differences between ctDNA detection technology, imaging, and blood tumor markers in monitoring tumor disease progression, and evaluate the correlation between ctDNA status after curative treatment and patient PFS and RFS. conditions: Ovarian Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED measure: DFS of enrolled patients for 2 years sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Soochow University city: Suzhou state: Jiangsu zip: 215006 country: China name: Jinhua Zhou role: CONTACT phone: +86 13914024750 email: jsjhzh@126.com name: Songbing Qin role: PRINCIPAL_INVESTIGATOR lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06283862 id: HUM00231159b id: VMR2022-03 type: OTHER_GRANT domain: Michigan, State of, Licensing and Regulatory Affairs, Department of 573000 briefTitle: MIVetsCan: Can-Coach Trial (Phase 2) overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-02 date: 2027-02 date: 2024-02-28 date: 2024-02-28 name: University of Michigan class: OTHER name: Michigan, State of, Licensing and Regulatory Affairs briefSummary: The goal of the MIVetsCan Can-Coach Trial is to test four coaching sessions to help Veterans with chronic pain use their own cannabis products more effectively to manage pain and related symptoms. conditions: Chronic Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to immediately receive 4 sessions of tailored guidance or to receive it after 12 weeks, as a waitlist control condition. primaryPurpose: PREVENTION masking: NONE count: 468 type: ESTIMATED name: Educational Session measure: Patient Global Impression of Change (PGIC) score measure: Self-report of pain (intensity or severity) from a numerical rating scale of 0-10 measure: Anxiety as measured by the score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile version 2.1 measure: Pain interference trends as measured by the score on the PROMIS-29 Profile version 2.1 measure: Sleep disturbance as measured by the score on the PROMIS-29 Profile version 2.1 measure: Suicidal ideation as measured by the Positive and Negative Suicide Ideation (PANSI) - Positive ideation measure: Suicidal ideation as measured by the Positive and Negative Suicide Ideation (PANSI) - Negative ideation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan city: Ann Arbor state: Michigan zip: 48105 country: United States name: Vivian Kurtz role: CONTACT phone: 734-998-7156 email: vkurtz@med.umich.edu name: Kevin Boehnke role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06283849 id: SON-2024-32671 briefTitle: Collaborative Solutions for Breaking up Sedentary Time in Black Older Adults With Type 2 Diabetes: The Interrupt Diabetes Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-01 date: 2026-05-01 date: 2024-02-28 date: 2024-02-28 name: University of Minnesota class: OTHER briefSummary: The disparate burden of Type 2 Diabetes (T2D) faced by Black individuals makes attention to preventing or delaying the development of T2D and its associated cardiovascular (CV) complications, essential.